Nine Months / Third Quarter Report 2010

Key Figures – Eurofins Scientific Group

According to International Financial Reporting Standards (IFRS)

Sales in EUR Million



EBITDA in EUR Million



Net operating cash flow in EUR Million



Average Number of Employees*



EUR = Euros
NM = first nine months of the year
CAGR: Compound Annual Growth Rate
*FTE = Full Time Employees

Company Profile

A global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the food, environmental and pharmaceutical sectors.

With about 8,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 40,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of bio-logical substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy to expand both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

Shareholders' information in short

Listings

NYSE Euronext Paris (since IPO on 24.10.1997)

Segments/ Indexes

Paris: SBF 120 & Next 150, SRD & Compartment B, Next Biotech

Industry Group/ Prime Sector

Pharma & Healthcare/Healthcare Providers

Codes

ISIN: FR 0000038259

Tickers

Paris: Reuters EUFI.PA, Bloomberg ERF FP

Nominal Capital (as of 30.09.2010)

EUR 1,423,427.20 (14,234,272 x EUR 0.10)

Simplified Ownership Structure (30.09.2010)

46% Martin family
54% free float

Investor Relations

Eurofins Scientific Group
Phone: +32 2 769 7383
E-mail: ir@eurofins.com

Internet

www.eurofins.com

Operating and Financial Review and Prospects

Financial figures in this report were prepared based on the International Financial Reporting Standards (IFRS). All accounts are consolidated at the Eurofins Scientific Group level. The Company's auditors have conducted a limited review on these accounts.

Dear Shareholders,

I am pleased to report a solid performance during the third quarter, where the Group delivered growth of nearly 8% in operating revenues and EBITAS* expansion of 52%. Year to date, EBITAS has climbed 64% on revenue growth of close to 6%. Higher efficiency as a result of the accelerated reorganization and the five year investment programme has positioned Eurofins to start maximising operating momentum and strengthen profit margins. The Group remains committed to completing its "homework" this year, and is on course to benefit from gradual economic recovery, positive operating trends, and a streamlined operation starting 2011.

Highlights of the quarter were as follows:

-Revenues grew 8% relative to Q3 2009 to EUR 175.4m, and is in-line with the growth rate achieved during the inflection point in the previous quarter. Year to date, revenues stand at EUR 494.0m, representing a 6% growth from the same period last year. Organic growth for Q3 2010 was 5%, and for NM 2010 was 4%.

-EBITDA** is up 35% in Q3 2010, at EUR 30.3m, on the back of a 348 basis point margin expansion, despite residual one-off reorganization costs. Adjusting for these non-recurring costs, clean*** EBITDA (before one-off reorganisation charges but after losses related to the Group's start-up operations) increased to EUR 34.5m, a 19.7% margin, versus EUR 27.5m and 16.8% margin in the same period last year. For NM 2010, EBITDA is at EUR 65.2m, implying a 13.2% margin, versus EUR 49.4m and 10.5% respectively for NM 2009.

-EBITAS increased 52% to EUR 19.7m in Q3 2010 versus EUR 13.0m in Q3 2009. In NM 2010, the increase was 64% (NM 2010 EUR 34.4m versus NM 2009 21.0m). Clean EBITAS also improved materially from EUR 30.8m in NM 2009 to EUR 43.8 in NM 2010.

-Net profit in Q3 2010 was EUR 11.4m, a 93% growth from Q3 2009 profit of EUR 5.9m. Year to date, net profit of EUR 15.8m for NM 2010 is five times the EUR 3.0m net profit for NM 2009. Significantly, these results were achieved despite the costs of expanding the network, including 15 start-ups in fast growing economies, and ca. EUR 10m in one-off costs incurred year to date from the reorganization programme, including discontinued operations.

-Net debt of EUR 197m as of September 30, 2010 implies net debt/equity of 0.90x and net debt/clean EBITDA of 1.8x, substantially improved from September 2009 levels of 0.94x and 2.3x respectively. This keeps the Group well within its debt covenant limits of 1.5x net debt to equity and 3.5x net debt to clean EBITDA.

-Net cash flow from operating activities increased by 40% to EUR 38.3m in NM 2010 (EUR 27.4m in NM 2009). Total Group Free Cash outflow**** narrowed significantly to just EUR 5.4m for NM 2010, compared to the EUR 18.1m outflow in NM 2009. Adjusting for the cash flow impact of the reorganization (EUR 14.5m in NM 2010 versus EUR 9.6m in NM 2009), the Group generated positive clean Free Cash Flow**** of EUR 9.1m versus a clean Free Cash outflow of EUR 8.5m in the same period last year.

During the third quarter, Eurofins maintained operating momentum, delivering revenue growth of almost 8%, largely the same growth rate achieved during the turnaround in Q2 2010. The food testing business continues to strengthen, posting robust growth across most markets as volumes continued to pick up ahead of a seasonally strong Q4. The uptick in demand that was seen in the previous quarter in the environmental testing business has been sustained, and should hold through in Q4 as well, as private and public agencies complete testing activities prior to the thick of the cold season. Results from the pharma business show a turnaround in order backlog, and general improvement in the project pipeline. Overall, the strong revenue growth is consistent with the gradual improvement in the broader economic activity across the world, but also highlights the Group's ability to benefit from the economic turnaround by leveraging its market position.

The wide margin expansion during the quarter, and in NM 2010, demonstrates the increased efficiency following the intensive investment programme in large, modern facilities over the last 5 years, and the acceleration in reorganization in the last 24 months to rationalize the network of laboratories and streamline costs. The investments are starting to pay-off with Q3 2010 delivering the highest EBITDA margin since 2006 at 17.3%, despite losses related to the rapid network expansion (15 start-ups), and the residual one-off costs from the reorganization and from discontinued operations.

Total costs came in at EUR 145.2m, a growth of 3% compared to Q3 2009, and represents less than half the rate of revenue growth for the period. One-off costs related to the reorganization during the quarter was EUR 4.3m, bringing total one-off costs year to date to EUR 9.4m. As previously communicated, the Group endeavours to complete the reorganization programme in 2010. This prudent strategy should contribute to continued margin expansion and improved profitability from 2011 onwards.

Improving profitability is also reflected in the strengthening of the Group's balance sheet. Cash and cash equivalents stood at EUR 105m at the end of September 2010, versus EUR 50m at the end of the same period last year, despite having deployed over EUR 50m from the OBSAAR proceeds to repay bilateral bank debts, thereby freeing up credit lines and further widening the Group's debt capacity. At the end of September 2010, net debt was EUR 197m, implying net debt/equity of 0.90x and net debt/clean EBITDA of 1.8x, having steadily improved in the past four quarters, from 0.94x and 2.3x respectively at the end of September 2009.

The Group's focus on profitability continues to translate to stronger cash generation. Higher revenues and stronger margins have resulted in a 22% rise in net cash from operating activities in Q3 2010 (EUR 19.0m versus EUR 15.6m in Q3 2009). The higher cash generated from operations has allowed the Group to generate Free Cash Flow of EUR 6.6m, 11% higher than in Q3 2009. Year to date, cash generated from operations has risen 40% relative to NM 2009, at EUR 38.3m. Higher operating cash flow, in addition to stable capital expenditures, has allowed the Group to cut total Free Cash outflows to just EUR 5.4m for NM 2010, compared to the EUR 18.1m outflow in NM 2009, despite having the bulk of the cash flow impact of one-off reorganization costs as planned. Adjusting for non-recurring costs (EUR 14.5m in NM 2010 versus EUR 9.6m in NM 2009), the Group actually generated clean Free Cash Flow of EUR 9.1m for NM 2010, compared to an outflow of EUR 8.5m in NM 2009.

The robust Q3 2010 results show that the intensive investment programme of the last five years and the benefits from the accelerated reorganization over the last 24 months are starting to come to fruition. The Group still has some way to complete its "homework" and is diligently reviewing measures to ensure the completion of the reorganization programme by the close of the year.

The intensive investment and reorganization programs position Eurofins well to benefit from the secular growth trends in the markets in which it operates in. The narrowing of costs as the Group comes to the tail-end of its intensive restructuring reorganization programme, and the steady reduction in start-up losses, should impact margins positively regardless of top line growth from 2011 onwards. The investments in a network of large, state of the art laboratories ensure Eurofins' leading market position is maintained, whilst the comprehensive reorganization will gradually and sustainably drive profitability.

As the results of the last two quarters demonstrate, the Group is on track to be able to self-finance organic growth, as focus on maximising returns is now translating to material improvement in Free Cash Flow generation.

The Group remains steadfast in achieving efficiency, optimising resources and maximising returns to shareholders. I would like to thank all our clients, employees and shareholders for contributing to our progress.

Sincerely,

Dr. Gilles G. Martin
CEO

*	EBITAS – Earnings Before Interest, Tax, Amortization of Intangible Assets related to acquisitions and impairment of goodwill and non-cash accounting charge for stock options
**	EBITDA – Earnings before interest, tax, depreciation and amortization
***	'clean' – a proforma presentation excluding one-off costs from reorganization and discontinued operations, but including losses related to network expansion (15 start-ups)
****	Free Cash (out)Flow – net cash flow provided by operating activities, less cash used in investing activities (but excluding acquisition payments) and interest and hybrid interest paid.

Operating Revenues

Group revenues posted robust growth of close to 6% in NM 2010 at EUR 494.0m, compared to EUR 468.1m for the same period last year. In Q3, revenues grew another 8% year on year, to EUR 175.4m, in-line with the strong growth delivered in Q2, which saw the first decisive turnaround in revenue trends across our markets since the economic downturn.

Breakdown of sales by region and as a % of sales:

EUR million	NM 10	%	NM 09	%
Benelux	**54.5**	*11.0*	**57.8**	*12.4*
British Isles	**31.6**	*6.4*	**27.8**	*5.9*
France	**96.2**	*19.5*	**88.7**	*19.0*
Germany	**114.9**	*23.3*	**106.4**	*22.7*
North America	**50.6**	*10.2*	**50.8**	*10.8*
Scandinavia	**97.4**	*19.7*	**95.5**	*20.4*
Other	**48.8**	*9.9*	**41.1**	*8.8*
Total	**494.0**	*100.0*	**468.1**	*100.0*

Further disclosures on quarterly sales are contained at the end of this section.

Across our markets, the trends in NM 2010 are encouraging, although we remain cognizant of the challenges in some countries. Strong market position in our core markets allow us to remain confident to grow our businesses. The food testing business continues to go from strength to strength, while the pick-up in the environmental business seen in Q2 has continued in Q3. There are also encouraging signs of recovery in the pharmaceutical business, as reflected in the increase in order backlog during the quarter. Additionally, there was a slight beneficial foreign exchange difference (ca. 2% year to date) from most non-Euro denominated countries.
Overall, the strong revenue growth outpaced the growth rate in the broader economy, and highlights the Group's ability to benefit from the economic turnaround by leveraging its leading position in the markets where it operates.

Profitability

The investment programme of the last five years and the acceleration in reorganization efforts over the last 24 months are clearly starting to pay off. Costs rose 2% in NM 2010, well below the rate of revenue growth. In Q3 2010, the 3% rise in costs (EUR 145.2m versus EUR 140.6m in Q3 2009) was less than half the revenue growth rate. Personnel costs, which comprise the biggest component of the Group's cost base, declined as a proportion of revenues from 49.9% in NM 2009 to 49.2% in NM 2010. In fact, the 6% growth in revenues in NM 2010 was achieved whilst the number of Full-time Employees (FTEs) remained constant over the relevant period, highlighting the increased efficiency within the Group. (Further disclosure on Group FTE at the end of the section.) Likewise, cost of purchased materials and services as a proportion of revenues is on a declining trend, coming in at 37.5% during NM 2010, versus 39.1% in NM 2009. Profitability, alongside revenue growth, is of ever-increasing focus for the Group, as evidenced by the 32% growth in EBITDA* for NM 2010 to EUR 65.2m, compared to EUR 49.4m for NM 2009, despite residual one-off restructuring costs. In Q3 alone, EBITDA grew 35% to EUR 30.3m (versus EUR 22.5m in Q3 2009), on the back of a 348 basis point margin expansion to 17.3%. Adjusting for one-off restructuring costs, recurring clean** EBITDA after start-up losses would have been EUR 34.5m, a margin of 19.7% (EUR 27.5m and 16.9% respectively for Q3 2009).

Higher revenues and stronger margins have boosted EBITAS*** in Q3 by 52% to EUR 19.7m, compared to EUR 13.0m in the same period last year. For NM 2010, EBITAS is 64% higher than NM 2009, at EUR 34.4m. Financial costs were higher in Q3 2010 compared to Q3 2009 due to the higher level of gross debt following the OBSAAR issuance at the end of June. However, this is partly offset by the somewhat lower effective tax rate in the quarter.

The group's net profit has nearly doubled in Q3 2010 to EUR 11.4m compared to EUR 5.9m in the same period last year. Year to date, net profit stands at EUR 15.8m, and is five times the NM 2009 net profit of EUR 3.0m. The surge in profit was driven by the recovery in top line growth and more importantly, margin expansion from higher efficiency as a result of the accelerated reorganization programme initiated during the economic downturn.

Balance Sheet

Group total assets stood at EUR 739.5m at the end of September 2010, compared to EUR 671.5m in the same period of 2009, due to higher cash balance from the OBSAAR issuance at the end of June 2010. Cash and cash equivalents stood at EUR 105.0m at the end of September (versus EUR 49.9m in the same period last year), despite having deployed over EUR 50m from the OBSAAR proceeds to repay bilateral bank debts, which has freed up even more credit lines and widens the Group's debt capacity.

The strong operating and financial results year to date has further improved the Group's debt profile versus the metrics set out in its debt covenants. Net debt at the end of Q3 2010 was EUR 197.0m, versus EUR 202.4m at the end of Q3 2009. This translates to a net debt to clean EBITDA ratio of 1.8x for September 2010, a vast improvement from 2.3x in September 2009. Net debt to equity also improved from 0.94x in September 2009 to 0.90x in September 2010. This means that the Group remains comfortably within the limits of its debt covenants, set out at 3.5x and 1.5x net debt to clean EBITDA and net debt to equity ratios respectively.

Net working capital has been reduced to 6.6% of revenues at the end of September 2010 from 7.6% in the same period last year. Nevertheless, it represents a slight uptick from 5.7% at the end of June, 2010 due to some seasonality.

Cash Flow and Liquidity

The operating momentum continues to strengthen the Group's cash flows. Net cash from operating activities rose 40% to EUR 38.3m in NM 2010, compared to EUR 27.4m in NM 2009, due to higher revenues, stronger margins and close working capital management.

The EUR 6.1m acquisition costs for NM 2010 relate mostly to deferred payments from previous acquisitions, and shows a 71% reduction from the same period in the previous year (EUR 21.0m in NM 2009). Lower acquisition costs in addition to broadly flat capital expenditures (EUR 25.2m for NM 2010 versus EUR 25.9m for NM 2009), has led to a 28% reduction in investment costs to EUR 34.1m for the period, translating to a EUR 13.2m savings over investments costs in NM 2009. As a result, Group Free Cash outflow**** significantly narrowed from EUR 18.1m in NM 2009 to just EUR 5.4m in NM 2010. Even more significantly, adjusting for the cash flow impact of one-off costs related to the reorganization (EUR 14.5m for NM

2010 versus EUR 9.6m for NM 2009), the Group generated positive clean Free Cash Flow**** of EUR 9.1m in NM 2010, compared to a clean Free Cash outflow of EUR 8.5m for the same period last year, implying a EUR 17.6m improvement over the last 12 months. Most of the one-off charges pertain to reorganization expenses charged to the profit and loss statement in 2009, but were payable in 2010, such as long-term lease payments. Hence, the phasing-out of these non-recurring expenses implies further cash flow improvement going forward.

Sales and Marketing

Eurofins has had another successful quarter, building on the solid developments in the first half of 2010. Confirming its position as the leading food testing service provider in the country, Eurofins Analytics in Nantes has extended its COFRAC LAB GTA 21 accreditation to the analysis of all organic contaminants across all food matrices, giving it the broadest scope amongst all private food testing laboratories in France. In line with the Group's commitment to public health and safety, Eurofins Cervac Ouest is now the only private laboratory that offers Premitest®, which enables identification of Salmonella serotypes using specific DNA fragments, allowing clients to take necessary action rapidly. Eurofins recently won a three year contract for analysis of Transmissible Spongiform Encephalopathies (TSE), more commonly known as Prion Disease, for the Belgian Federal Agency for Safety of the food Chain (FASFC). The Group's Italian business has developed one of the most comprehensive pesticides screening package involving some 440 molecules, which is expected to facilitate market share gains. Within our newer markets, the Brazilian Ministry for Agriculture (MAPA) has extended the scope of Eurofins' accreditation for Pesticides testing, allowing the Group to expand its product portfolio for official samples analysis for special monitoring programs by the Brazilian government.

The pharma business continues to make significant inroads. Eurofins Medigenomix, a Competence Center for genetic analyses, and Boehringer Ingelheim, an international research-driven pharma company, concluded a long term service agreement (LSA) for DNA banking, and a master service agreement (MSA) for pharmacogenetic and pharmacogenomic services. Both services support Boehringer Ingelheim's R&D activities and contribute to the development of safe and effective drugs.

Consistent with the Group's focus on maintaining leading market position across its industry lines, Eurofins Denmark further increased its market share in the public water testing market during the quarter by winning a large national multi-year tender. A leading market position enables the Group to standardize testing methods to a greater degree, increasing efficiency whilst maintaining quality. Eurofins Italy won a bid to provide air monitoring services to utilities provider ACEGAS APS for a period of two years.

Elsewhere, the Group continues to gain operating momentum in China, aggressively gaining clients, which now stand at 160 small and medium-sized enterprises (SMEs) just 12 months after the launch of our Chinese marketing initiatives. The success of the recent Eurofins-sponsored seminars on RoHS and REACH testing services, and MET certification, establishes the Group's reputation in the testing service industry in the region. Additionally, the integration of Eurofins' food, pharma and product testing services, evident in the newly-launched Eurofins China's website, is a powerful marketing tool reflecting the Group's competencies.

R&D, Infrastructure and IT

As Eurofins' intensive 5-year investment programme to rationalize its network of laboratories comes to a close this year, the Group is now set to benefit from a streamlined backbone and infrastructure, including its proprietary LIMS IT network, state of the art Competence Centers, and the broadest portfolio of testing services. To illustrate this, a new purpose-built laboratory for all microbiology facilities for Western France is due to come on stream at the beginning of 2011. In the US, the Group's new, state of the art food laboratory center in Des Moines, Iowa, allows Eurofins to handle specialty food and feed projects, and has already achieved ISO 17025 accreditation.

As previously reported, the Clinical Pharmacology Unit in France has expanded its capacity to 100 beds, positioning Eurofins well for early clinical development phases. Medinet, the central laboratory for clinical studies, is now fully operational at the new facility in Shanghai.

Eurofins MWG Operon strengthens its position as the leading expert in next generation sequencing (NGS) with the purchase of a Roche GS Junior. The integration of the new system in the NGS service pipeline allows Eurofins to maintain the quality of high throughput sequencing projects and develop new applications more efficiently and more effectively.

Eurofins' proprietary LIMS IT backbone and network has been replicated and rolled-out in China, which will give the Group greater competitive edge on the back of standardized testing, transparent process from start to finish, and faster turnaround time.

Eurofins-On-Line (EOL), a proprietary web-based application that allows customers to electronically manage their data and communicate with their Eurofins laboratories in real time, has gone live in key Eurofins markets. EOL significantly reduces time and logistical process from sample registration through to the generation of analytical results for the customers, and cuts Eurofins' laboratory costs for sample registration. The Group expects to be able to provide the service to most of its customers across its businesses in Europe and the US by next year.

Acquisitions and Geographic Expansion

Eurofins has opened a new food testing laboratory in Bangalore, India, in September, bolstering the Group's existing local operations. The new facility not only fulfills demand from major clients, but positions the Group to ride the wave of both new regulations for the local market, and the exponential growth in exports of agricultural commodities and food products. Eurofins' growing presence in the region also reflects the Group's commitment to be present in markets where existing customers have an increasing need for testing services.
The new sales hub at Recife in the Pernambuco State in Brazil, expands Eurofins' Latin American footprint. Pernambuco, which is in the northeast region, is one of the fastest food production growth areas, and the biggest fruit production zone in Brazil.

Eurofins is well positioned to take advantage of compelling opportunities as and when they arise, as evidenced by small-scale acquisitions and asset swaps concluded just after the close of the third quarter in France. The Group continues to monitor the competitive landscape and remain committed to consolidating the market. However, Eurofins maintains its current policy for low-key M&A activity, focusing on fully integrating and extracting value from previous acquisitions.

Other corporate news

Reflecting the Group's commitment to high standards of corporate governance, Mr. Stuart Anderson has been appointed to the Conseil d'Administration in Q2 2010 as an independent, non-executive director. Mr. Anderson, a seasoned food industry professional, will also be chairing the Audit Committee.

Eurofins has officially delisted from its second quotation on the Prime Standard of the Deutsche Börse. As communicated previously, the board took the decision to delist due to the low daily trading volumes in the shares on the Frankfurt market, which did not justify the costs of maintaining the second listing. The last day of trading on the Frankfurt Stock Exchange was on 10 September, 2010. Eurofins shares are now solely listed on the NYSE Euronext Paris.

Outlook

The positive trends that had started in Q2 2010 have continued during Q3. We remain confident that the Group will continue to deliver solid growth, underpinned by the 6% revenue growth already achieved year to date, which is already 2 percentage points above the forecast full year global growth of just over 3%*****.

The efficiency gains from investments and reorganization have allowed the Group to rein-in and stabilize costs, boosting margins. On the other hand, the narrowing of one-off costs as the Group comes to the tail-end of its intensive reorganization programme, and the steady reduction in start-up losses, should impact margins positively regardless of top line growth from 2011 onwards. For the remainder of 2010, the Group expects, at a minimum, to maintain the strong profitability achieved in Q3 2010. Moreover, despite having the majority of the cash flow impact of the rationalization programme this year, the Group expects the improvement in Free Cash Flow generation to continue for the remainder of the year. In the medium term, improving profitability and lower capital expenditures as a proportion of revenues should allow the Group to sustainably finance its planned organic growth.

Employees

The average weighted number of Full Time Employees for the NM period to 30 September was 7,163, compared to 7,148 at NM 2009. Headcount for the Group at 30 September was 8,187 (8,174 at 30.09.2009).

Total personnel costs for the Group, including social security and pension costs, were EUR 243.1m, which represents 49.2% of Group revenues for the nine months (NM 2009 EUR 233.4m, 49.9%).

As of	**30.09.2010**	30.09.2009
Benelux	**707**	767
British Isles	**428**	494
France	**1,398**	1,422
Germany	**1,857**	1,730
North America	**618**	628
Scandinavia	**1,129**	1,253
Other	**1,026**	854
Total	**7,163**	7,148

Employee numbers are weighted average "Full time equivalents" (FTE), i.e. the figures are weighted by the time that (acquired) laboratories are fully consolidated in the Group.

Capital Structure

The Martin family, either directly or through their holding in Analytical Bioventures SCA, currently holds 46% of the shares in Eurofins Scientific and 53% of the voting rights. The remainder is free float.

The summary of Directors' Holdings as at 30 September 2010 is shown in the table below:

As of 30.09.2010	No. of Shares	No. of Stock Options
Gilles G. Martin	1	0
Valérie Hanote	1	0
Wicher R. Wichers	20,001	8,500
Yves-Loïc Martin	14,546	0
Stuart Anderson	355	0

Analytical Bioventures SCA, which is controlled by Gilles and Yves-Loïc Martin, holds 6,559,570 shares

* EBITDA – Earnings before interest, tax, depreciation and amortization
** clean - a proforma presentation excluding one-off costs from reorganization and discontinued operations, but including losses related to network expansion (15 start-ups)
*** EBITAS – Earnings Before Interest, Tax, Amortization of Intangible Assets related to acquisitions and impairment of goodwill and non-cash accounting charge for stock options
**** Free Cash (out)Flow – net cash flow provided by operating activities, less cash used in investing activities (but excluding acquisition payments) and interest and hybrid interest paid.
***** World Bank Global GDP growth forecast for FY 2010.

Breakdown of sales by region:

EUR million	NM 10	NM 09	Q3 10	Q3 09	Q2 10	Q2 09	Q1 10	Q1 09
Benelux	**54.5**	57.8	**18.0**	18.1	**19.0**	20.0	**17.5**	19.6
British Isles	**31.6**	27.8	**11.1**	9.7	**11.0**	9.7	**9.5**	8.4
France	**96.2**	88.7	**33.2**	30.0	**33.0**	29.8	**29.9**	28.9
Germany	**114.9**	106.4	**42.6**	39.2	**38.1**	35.3	**34.1**	31.9
North America	**50.6**	50.8	**17.8**	17.3	**17.4**	16.5	**15.4**	16.9
Scandinavia	**97.4**	95.5	**33.9**	33.8	**34.4**	31.4	**29.1**	30.3
Other	**48.8**	41.1	**18.6**	14.9	**16.5**	14.0	**13.6**	12.2
Total	**494.0**	468.1	**175.4**	163.1	**169.4**	156.8	**149.1**	148.2

Consolidated Financial Statements

Consolidated Profit and Loss Statement

January 1, 2010 to September 30, 2010

€ Thousand	**Q3/ 2010**	**Q3/ 2009**	**NM/ 2010**	**NM/ 2009**
Revenues	**175,419**	**163,088**	**493,974**	**468,101**
Cost of purchased materials and services	-63,515	-61,575	-185,217	-183,164
Personnel expenses	-80,660	-77,368	-243,103	-233,350
Other operating income and expenses, net	-982	-1,679	-483	-2,216
EBITDA	30,262	22,466	65,171	49,371
Depreciation and amortisation	-10,518	-9,510	-30,783	-28,402
EBITAS*	**19,744**	**12,956**	**34,387**	**20,969**
Non cash accounting charge for stock options (S.O.)	-574	-551	-1,651	-1,650
Impairment of goodwill and amortisation intangible assets related to acquisitions	-270	-301	-806	-1,629
EBIT after non cash accounting charge for S.O., impairment of goodwill and amortisation of intangible assets related to acquisitions	18,900	12,104	31,930	17,690
Finance income	363	632	815	1,756
Finance costs	-4,043	-3,257	-9,902	-11,205
Financial result	-3,680	-2,625	-9,087	-9,449
Share of (loss)/ profit of associates	24	55	125	117
Result before income taxes	15,244	9,534	22,968	8,358
Income tax expense	-3,890	-3,637	-7,128	-5,343
Net profit for the period	**11,354**	**5,897**	**15,840**	**3,015**
Attributable to:				
Equity interest	11,155	5,884	14,471	2,221
Non Controlling Interest	199	13	1,369	794
Earnings per share (basic) in € - Total	0.79	0.42	1.02	0.16
Earnings per share (basic) in € - attributable to hybrid capital investors	0.14	0.14	0.43	0.43
Earnings per share (basic) in € - attributable to equity holders	0.64	0.27	0.59	-0.27
Earnings per share (diluted) in € - Total	0.72	0.38	0.94	0.14
Earnings per share (diluted) in € - attributable to hybrid capital investors	0.13	0.13	0.39	0.39
Earnings per share (diluted) in € - attributable to equity holders	0.59	0.25	0.55	-0.25
Weighted average shares outstanding (basic)	14,208	14,178	14,208	14,178
Weighted average shares outstanding (diluted)	15,430	15,346	15,430	15,346

* EBITAS : EBIT before non cash accounting charge for S.O., impairment of goodwill and amortisation of intangible assets related to acquisitions

Statement of Comprehensive income

As of September 30, 2010

€ Thousand	**NM/ 2010**	**NM/ 2009**
Net profit for the period	**15,840**	**3,015**
Currency translation differences	11,185	656
Financial instruments	-2,980	-1,970
Other comprehensive income for the period, net of tax	**8,205**	**-1,314**
Total comprehensive income for the period	**24,045**	**1,701**
Attributable to:		
Equity interest	22,688	1,255
Non controlling interest	1,357	446

Consolidated Balance Sheet

As of September 30, 2010

€ Thousand	30.09.2010	31.12.2009
Property, plant and equipment	137,293	135,002
Goodwill	246,302	239,313
Other intangible assets	28,856	29,943
Investments in associates	2,564	2,260
Financial assets, trade and other receivables	6,996	5,487
Deferred tax asset	18,409	15,643
Derivative financial instruments	0	0
Total non current assets	**440,420**	**427,648**
Inventories	8,224	7,769
Trade accounts receivable	155,848	145,298
Prepaid expenses and other current assets	23,716	20,826
Corporate tax receivable	6,296	3,398
Cash and cash equivalents	105,024	54,360
Total current assets	**299,108**	**231,651**
Total assets	**739,528**	**659,299**
Share capital	1,424	1,421
Other reserves	64,437	52,882
Hybrid capital	100,000	100,000
Retained earnings	46,973	42,321
Shareholders' equity – part of the Group	212,834	196,624
Non controlling interest	5,662	6,410
Total shareholders' equity	**218,496**	**203,034**
Borrowings	36,616	97,283
OBSAAR Bonds	205,991	118,057
Derivative financial instruments	7,435	4,455
Deferred tax liability	10,607	7,127
Account payable on investment	13,350	20,603
Pension accrual	13,301	12,411
Provisions for other liabilities and charges	13,203	18,495
Total non current liabilities	**300,503**	**278,431**
Borrowings	43,707	22,735
OBSAAR Bonds	15,712	0
Trade accounts payable	48,336	50,558
Advance payments received and deferred revenues	17,160	16,671
Corporate tax due	9,327	7,597
Account payable on investment	6,589	1,359
Other current liabilities	79,698	78,914
Total current liabilities	**220,529**	**177,834**
Total liabilities and shareholders' equity	**739,528**	**659,299**

Consolidated Cash Flow Statement

January 1, 2010 to September 30, 2010

€ Thousand	NM/ 2010	NM/ 2009
Cash flows from operating activities		
Result before income taxes	**22,968**	**8,358**
Adjustments for:		
Depreciation and amortisation	31,588	30,031
Increase/ decrease in provisions and accruals	-5,709	540
Losses/ gains on the disposal of fixed assets, investments in associates	-631	441
Non cash accounting charge for stock options	1,568	1,566
Financial income and expense, net	8,273	9,440
Expense/ income from investments (equity method)	-125	-116
Derivative financial instruments – income statement	0	0
Change in net working capital	-12,298	-16,094
Cash generated from operations	**45,634**	**34,166**
Income taxes paid	-7,368	-6,773
Net cash provided by operating activities	**38,266**	**27,393**
Cash flows from investing activities		
Acquisitions of subsidiaries, net of cash acquired	-6,065	-20,963
Proceeds from sale of a subsidiary, net of cash transferred	-36	0
Purchase of property, plant and equipment	-25,219	-25,906
Purchase of intangible assets	-4,442	-4,064
Proceeds from sale of property, plant and equipment	783	1,482
Purchase net of sales of investments and financial assets	160	-9
Interest received	732	2,211
Net cash used in investing activities	**-34,087**	**-47,249**
Cash flows from financing activities		
Proceeds from issuance of share capital	404	348
Proceeds from short or long term borrowings	1,924	2,280
Cash repayments of amounts borrowed	-71,262	-53,523
OBSAR Bonds	173,867	0
Cash repayments of OBSAR Bonds	-70,291	-1,320
Dividends to shareholders	-1,421	-1,416
Dividends to non controlling interest net of capital increase paid to/by non controlling interests	-1,208	-1,509
Hybrid interest paid	-8,083	-8,081
Interest paid	-7,630	-11,135
Net cash provided by financing activities	**16,300**	**-74,356**
Net effect of currency translation in cash and cash equivalents	1,276	328
Net increase (decrease) in liquid funds	**21,755**	**-93,884**
Cash and cash equivalents and bank overdrafts at beginning of period	52,254	127,854
Cash and cash equivalents and bank overdrafts at end of period	**74,009**	**33,970**

Consolidated Statement of Changes in Equity

As of September 30, 2010

€ Thousand	Shareholder's equity part of the group				Non Controlling Interests	Total equity
	Share capital	Other reserves	Hybrid bonds	Retained earnings		
Balance at January 1, 2009	**1,416**	**49,086**	**100,000**	**62,084**	**6,533**	**219,119**
Currency translation differences	0	638	0	31	-13	656
Financial instruments	0	0	0	-1,970	0	-1,970
Non controlling interest transfer	0	0	0	335	-335	0
Total income / expense recognised directly in equity	0	638	0	-1,604	-348	-1,314
Net profit	0	0	0	2,221	794	3,015
Total income recognised in 2009	0	638	0	617	446	1,701
Issue of share capital	4	344	0	0	0	348
Deferred taxes on net investment	0	0	0	-258	0	-258
Non cash accounting charge for stock options	0	0	0	1,566	0	1,566
Deferred distribution on Hybrid capital	0	0	0	-6,106	0	-6,106
Dividends	0	0	0	-1,416	-1,769	-3,185
Non controlling interest arising on business combinations	0	0	0	0	1,351	1,351
Balance at September 30, 2009	**1,420**	**50,068**	**100,000**	**56,487**	**6,560**	**214,534**
Balance at January 1, 2010	**1,420**	**52,882**	**100,000**	**42,321**	**6,410**	**203,035**
Currency translation differences	0	11,154	0	3	29	11,185
Financial instruments	0	0	0	-2,980	0	-2,980
Non controlling interest transfer	0	0	0	41	-41	0
Total income / expense recognised directly in equity	0	11,154	0	-2,937	-12	8,205
Net profit	0	0	0	14,471	1,369	15,840
Total income recognised in 2010	0	11,154	0	11,534	1,357	24,045
Issue of share capital	4	400	0	0	70	474
Issue of BSAR	0	0	0	316	0	316
Deferred taxes on net investment	0	0	0	0	0	0
Non cash accounting charge for stock options	0	0	0	1,568	0	1,568
Deferred distribution on Hybrid capital	0	0	0	-6,063	0	-6,063
Specific dividends to MWG AG non controlling interests	0	0	0	-349	0	-349
Dividends	0	0	0	-1,421	-977	-2,398
Potential payment in shares arising on business combinations	0	0	0	0	0	0
Non controlling interest arising on business combinations	0	0	0	-934	-1,199	-2,133
Balance at September 30, 2010	**1,424**	**64,437**	**100,000**	**46,973**	**5,662**	**218,496**

Interim Notes

General

We inform you that these Interim Notes are summarised.

1. Accounting policies

Eurofins condensed interim financial statements for the nine months period ending 30 September 2010 have been prepared according to IAS 34 – Interim financial reporting standard as adopted by the European Union.

As condensed interim financial statements, they do not include all information required by IFRS framework for the preparation of annual financial statements and have to be read in relation with the Group consolidated financial statements prepared for the year-end 2009 in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

As described below, the accounting policies applied are consistent with the policies applied in the financial statements for the accounts closed at the end of 2009.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

The following standards, amendments and interpretations to published standards are mandatory for accounting periods since 1 January 2010. The Group did not early adopt any of these standards, amendments and interpretations in previous reporting periods.

- IFRS 2 (Amendment), 'Group cash-settled and share-based payment transactions'
- IFRS 3 (Revised), 'Business combinations'. The revised IFRS 3 recommends the use of the acquisition method for business combinations and is significantly different from the previous standard. All price adjustments to the purchase a business are to be classified as recorded at fair value at the acquisition date. After a period of 12 months, any adjustments will be booked in the income statement. Taking control of a subsidiary by step-acquisition conditions the recognition of a gain/ loss on the percentage already owned or the loss of control generates the recognition of a gain/ loss on the percentage still held. These different elements increase the volatility on the net profit of the Group.
  There is a choice on an acquisition-by-acquisition basis to measure the full or partial goodwill. Transaction costs should be booked as expenses. The Group has applied the revised IFRS 3 prospectively to business combinations since 1 January 2010.
- IFRS 5 (Amendment), 'Non current assets held for sale and discontinued operations'
- IFRS 7 (Amendments,) 'Financial Instruments: Disclosures'
- IFRS 8 (Amendments), 'Operating segments'
- IAS 1R (Amendment), 'Presentation of financial statements'
- IAS 7 (Amendment), 'Statement of Cash Flows'
- IAS 10 (Amendment), 'Events After the Balance Sheet Date'
- IAS 12 (Amendment), 'Income Taxes'
- IAS 16 (Amendment), 'Property, Plant and Equipment'
- IAS 17 (Amendment), 'Leases'
- IAS 21 (Amendment), 'The Effects of Changes in Foreign Exchange Rates'
- IAS 27 (Revised), 'Consolidated and separate financial statements',
- IAS 28 (Amendment), 'Investments in associates'
- IAS 31 (Amendment), 'Interest in joint ventures' (effective from July 2009).
- IAS 32 (Amendment), 'Financial Instruments: Presentation'
- IAS 33 (Amendment), 'Earnings per Share'
- IAS 34 (Amendment), 'Interim Financial Reporting'
- IAS 36 (Amendment), 'Impairment of Assets'
- IAS 37 (Amendment), 'Provisions, Contingent Liabilities and Contingent Assets'
- IAS 38 (Amendment), 'Intangible assets'.
- IAS 39 (Amendment), 'Financial instruments'
- IFRIC 9, 'Reassessment of embedded derivatives'
- IFRIC 16, 'Hedges of a net investment in a foreign operation'
- IFRIC 17, 'Distribution of non-cash assets to owners'
- IFRIC 18, 'Transfers of assets from customers'.

Other Interpretations of existing standards that are not yet effective and not relevant for the Group's operations

- IFRIC 14 (Amendment), 'Prepayments of a minimum funding requirements'
- IFRIC 19, 'Extinguishing financial liabilities with equity instruments'

The additional disclosures required will be presented for the first time in the 2010 annual financial statements as they are not material for an understanding of the current interim period.

2. Segment information

Geographical segments
Although the Group's business is managed on a worldwide basis, it operates in eight main geographical areas. These are Benelux, France, Germany, North America, Scandinavia, British Isles (United Kingdom + Republic of Ireland), Other European countries and Other Rest of the World countries.

€ Thousand Revenues	NM/ 2010	NM/ 2009
Benelux	54,493	57,805
France	96,152	88,737
Germany	114,856	106,402
North America	50,619	50,759
Scandinavia	97,475	95,518
British Isles	31,592	27,776
Other European countries	34,150	31,843
Other countries	14,637	9,261
Total	493,974	468,101

Revenues are based on the production country. For confidentiality reasons, the operating income by geographical areas is not provided.

3. Change in the scope 2010

During the third quarter, the group concluded a small asset swap to focus its food testing offering in France. This change of scope has no relevant impact on the comparability of the financial statements.

4. Balance sheet impact of the change of scope

During the first nine months of 2010 the Company continued to acquire all or part of non controlling interests held in Group companies. Furthermore, the Group also continued to pay amounts due to former-shareholders of previously purchased companies.

The fair values of assets and liabilities are as follows:

€ Thousand	NM/ 2010
Property, plant and equipment	-954
Intangible assets	64
Goodwill and intangible assets related to an acquisition	1,959
Financial assets	-1,592
Current assets excluding Cash	528
Corporate tax receivable	0
Cash	36
Current liabilities	-235
Corporate taxes due	2
Borrowings	0
Account payable on investment	-3,519
Deferred taxes	-130
C/A not consolidated	0
Pension accrual	103
Provisions for risks	-228
Losses/ gains on the disposal of subsidiaries	712
Shareholders equity	-933
Non controlling interest	-1,878
Total purchase price paid to date	**-6,065**
Less cash	-36
Cash outflow on change of scope	**-6,101**

Divided into:

Cash outflow on acquisition	-6,065
Proceeds from disposals of a subsidiary, net of cash transferred	-36

5. Contingencies

The contingencies are described in more detail in the Annual Report 2009 in the Note 4.2.
The liabilities/ borrowings listed below are already included in the Group's balance sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets.

€ Thousand	**30.09.2010**	**31.12.2009**
Bank borrowings secured over buildings and assets	15,796	19,072
Leases secured over buildings and assets *	4,469	5,868
Bank borrowings secured by covenants and financial assets	0	0
Bank borrowings & OBSAAR secured by covenants	248,364	207,524
Total	268,629	232,464

* Lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default.

As September 30 2010 the cash and cash equivalents and bank overdrafts are € 74,009 k (Note 8).

Detail of specific contingencies linked to acquisitions:

Rights to acquire or sell additional shares of a company have been signed at a formula price already fixed to be exercised during the period 2010-2015. The contingencies linked to the right to acquire or sell shares in this company (not yet booked in the consolidated balance sheet) are estimated at an amount of € 0.22m.

6. Changes in Equity and OBSAAR

Share capital: At September 30 2010, the total number of ordinary shares is 14.2 million shares with a par value of € 0.10 per share. All issued shares are fully paid.
During the first nine months of 2010, the share capital increased by 29,748 new shares of which 29,048 new shares by exercise of employee stock options and 700 new shares by exercise of partial & optional acquisition price payments in Eurofins shares.
As at 30 September 2010, the Company did not own any of its own shares (number of own shares at December 31, 2009: 0).

Financial instruments:
In order to hedge the Group's exposure to interest rates fluctuations particularly related to the 2006 and 2010 OBSAAR bonds, the Group has concluded some hedging contracts in order to swap its floating interest rate against a fixed rate. These contracts are either with immediate or deferred effect.
Principal amount hedged with a fixed rate is € 100m as of 30 September 2010. In addition, the Group concluded some interest rate hedging contracts with deferred effective date for the period December 2010 to June 2017 for a total nominal amount comprised between € 50m and € 150m.
The fair value of all these hedging instruments is estimated at an expense of € 7.4 m as of 30 September 2010.

Hybrid Bonds:
The structure of the hybrid bond ensures that it is recognized as a component of equity in accordance with IAS 32. For this reason, the tax-deductible interest payments are not included in interest expense, but accounted for in the same way as dividend obligations to shareholders. The interest accounted for during the first nine months amounts to € 6,063k.

Bonds with redeemable Warrants attached (OBSAAR 2010):
In June 2010, the Company issued OBSAAR bonds (French acronym for *"Obligations à bons de souscription et/ou d'acquisition d'actions remboursables*") for a nominal amount of € 176m to increase the average maturity of its financial debt and to finance the development of its laboratory network.
The principal characteristics are as follows:

- 295,990 Bonds, in denominations of €594.60 per bond;
- Interest rate: Euribor 3 months + 1.75% p.a. payable on a quarterly basis;
- Redemption: in three equal tranches on 29 June 2015, 29 June 2016 and 29 June 2017;
- The net proceeds is €173.9m and the costs of the transaction have been capitalised and will be expensed along the maturity of the bonds;
- 1 warrant (BSAAR) is attached to each bond (Obligation), ie. a total of 295,990 warrants, 2 warrants giving the right to subscribe or purchase 1 Eurofins share at a price of €40 per share. Exercise of the warrants will therefore potentially lead to the issue of a maximum of 147,995 shares, ie. a maximum dilution of 1.04% of the existing number of outstanding shares at the time of the OBSAAR issue;
- The bonds are listed on Euronext Paris from the 29 June 2010 under ISIN FR0010891770;
- The warrants will be listed on Euronext Paris from the 30 June 2012 under the ISIN code FR0010891796. They will only be exercisable or transferable from 30 June 2012 to 29 June 2017.

A part of the 2006 Bonds held by the banks in the Consortium and other holders of 2006 Bonds have been bought back up to a maximum amount corresponding to their effective respective subscription amount to the new issue OBSAAR, issued in June 2010. This repurchase of 2006 bonds have been made at par value increased by the amount of accrued interest. Eurofins has so repurchased 53.251 of its 2006 Bonds for an aggregate principal amount of € 70.3m at a unit price per 2006 Bond of EUR 1,320 increased by the amount of accrued interest.

7. Stock option plans

Stock options are granted to directors and employees. Movements in the number of share options outstanding are as follows (amounts in thousands):

At beginning of the year	930
Options granted	126
Options exercised	-29
Options expired	-31
At end of the period	**996**

8. Cash and Cash equivalents

€ Thousand	**30.09.2010**
Cash and cash equivalents - Balance Sheet	105,024
Operational overdrafts	-31,015
Cash and cash equivalents and bank overdrafts at end of period - Cash flow	**74,009**

9. Related-party transactions

There are no material changes concerning the related-party transactions (mainly rent) compared to the Note 4.8 in the Annual report.

10. Post closing events

After the period end Eurofins acquired a company in the area of an environmental testing in France.

PricewaterhouseCoopers Audit
63 rue de Villiers
92208 NEUILLY SUR SEINE cedex

HLP Audit
4 rue Amédée Ménard
BP 32532
44325 Nantes Cedex 03

STATUTORY AUDITORS' REVIEW REPORT ON THE FINANCIAL INFORMATION FROM JANUARY 1^{ST} TO SEPTEMBER $30^{TH,}$ 2010

To the Shareholders,

EUROFINS SCIENTIFIC SE
Rue Pierre Adolphe Bobierre
Boîte postale 42301
44323 Nantes cedex 3

This is a free translation into English of the Statutory Auditors' review report issued in French and is provided solely for the convenience of English speaking readers. This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.

At your request and as statutory auditors of your company, we hereby report to you on the accompanying condensed interim consolidated financial statements of Eurofins Scientific SE Company for the period January 1^{st} to September 30^{th}, 2010.

These condensed interim consolidated financial statements are the responsibility of the Company's management. Our role is to express a conclusion on these financial statements based on our review.

We conducted our review in accordance with professional standards applicable in France. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 - the standard of IFRSs as adopted by the European Union applicable to interim financial information.

Neuilly-sur-Seine and Nantes, November 5, 2010

The Statutory Auditors

PricewaterhouseCoopers Audit

Benoît PINOCHE

HLP Audit

Jacques HERON